Seattle Genetics Inc. (SGEN) Reports Q4 Loss of $0.24, Sales Top Expectations
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Price: $228.74 --0%
Financial Fact:
Revenue from collaboration and license agreements: 23.97M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Revenue from collaboration and license agreements: 23.97M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Seattle Genetics Inc. (NASDAQ: SGEN) reported Q4 EPS of ($0.24), $0.07 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $39.12 million.
For earnings history and earnings-related data on Seattle Genetics Inc. (SGEN) click here.
For earnings history and earnings-related data on Seattle Genetics Inc. (SGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- CoStar Group acquires Zonda for $800M, adding new home data
- Zurn Water Solutions (ZWS) Reiterated at Buy by Stifel on New Product Development Momentum
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
